+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 18Years - 65Years
All Genders
ID07144462

Evaluating Safety and Early Effectiveness of NEUK203-215 Injection with Fludarabine and Cyclophosphamide in Adults 18 to 65 With Difficult-to-Treat Autoimmune Diseases in China

Led by Neukio Biotherapeutics (Shanghai) Co., Ltd. · Updated on 2026-07-15

8

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety, tolerability, and preliminary effectiveness of NEUK203-215, a healthy donor allogeneic CD19BCMA-targeted CAR-NK cell product, in adults with severe, treatment-resistant autoimmune diseases. This early phase 1 study aims to provide initial clinical evidence about the drugs effects in patients with relapsed or refractory conditions such as systemic lupus erythematosus, diffuse systemic sclerosis, inflammatory myopathy, or autoimmune bullous dermatosis. Participants receive NEUK203-215 Injection along with the drugs Fludarabine and Cyclophosphamide at specified doses on specified days. The study uses a single treatment group design and plans an interim analysis when half of the total participants have enrolled to assess safety, tolerability, clinical response trends, and pharmacokinetic and pharmacodynamic properties. During the study, participants are monitored for adverse events, serious adverse events, and dose-limiting toxicities for up to 12 months after the NEUK203-215 infusion. Researchers collect data on safety and initial clinical responses to evaluate the treatments impact. The total participation period extends up to one year post-infusion to ensure thorough safety follow-up and evaluation.

CONDITIONS

Brief Title

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune Diseases

Research Team

H

Huji Xu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here